Comparison of effectiveness of methylcobalamin, alpha lipoic acid and vitamin B groups with placebo to control diabetic neuropathy syndrome in type 2 diabetes.

Abba Darou Teb Co.0 个研究点目标入组 500 人开始时间: 待定最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•Male or female patients with diabetes mellitus type 2 and having peripheral neuropathy symptoms with =2 neuropathic pain scale scores.
•The age group must be between 18-80 years old.
•Symptomatic conditions with neuropathic pain, numbness, tingling & burning sensation in the extremities for at least 1 month before enrolling in the study.
•Consent and compliance with all aspects of the study protocol, methods, and providing data during follow up contact.

•Presence of foot ulcer.
•Presence of peripheral vascular disease (non-palpable foot pulses, intermittent claudication).
•Patients who are contraindicated with Methylcobalamin, Alphalipoic acid, folic acid, or vitamin B6 and B1 usage.
•Pregnant or lactating women.
•Patients with a history or presence of Stroke, Alzheimer's Disease, Bell's Palsy, Parkinson's Disease, Epilepsy and Seizures, psychiatric and other neurological disorders.
•Patients who are known cases of the kidney disorders.
•Hypothyroidism.
•Decompensated cirrhosis.
•Patients who consume alcohol or have a history of alcohol dependency followed by any current use.
•Current use or history of having received study investigational drugs or participated in any other clinical trial which ended in the preceding three months or is currently ongoing.

发起方

Abba Darou Teb Co.